Search Results 211-220 of 16651 for alopecia

  1. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study - Mayo Clinic

    Skin disorders (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic treatment; - Conditions not expected to recur in the absence of an external ...

  2. Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma - Mayo Clinic

    Vitiligo or alopecia;; Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; or; Psoriasis not requiring systemic treatment ...

  3. LC-MS/MS lowers diagnostic thresholds for androgen-producing tumors or pathological hyperandrogenism in women - Mayo Clinic

    52 (58%) women were diagnosed with polycystic ovary syndrome (PCOS). Women with APT were more likely to have male-pattern alopecia documented on physical ...

  4. Hairy cell leukemia - Symptoms and causes - Mayo Clinic

    This slow-growing cancer doesn't always need immediate treatment. When hairy cell leukemia treatment is needed, it usually starts with chemotherapy.

  5. A Study to Evaluate the Optune® (Tumor Treating Fields) Concomitant with RT & TMZ to Treat Newly-diagnosed Glioblastoma - Mayo Clinic

    CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting);; Significant liver function impairment - AST or ALT > 3 times the upper limit ...

  6. Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer - Mayo Clinic

    Experienced resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If patient underwent major surgery or ...

  7. Study of Magrolimab Combination Therapy to Treat Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer - Mayo Clinic

    previously administered agent. - Note: individuals with any grade neuropathy or alopecia are an exception to this criterion and will qualify for the study ...

  8. Head and neck cancers - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Birthmarks, Vulvar skin disorder, Rosacea, Pigmentation disorder, Telogen ...

  9. A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC - Mayo Clinic

    Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy (excluding alopecia). Participants with ≥grade 2 pneumonitis from prior ...

  10. A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis - Mayo Clinic

    Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia;; Women of child bearing potential (WCBP), defined ...